Technical Analysis for ENTA - Enanta Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 68.97 -1.32% -0.92
ENTA closed down 1.32 percent on Tuesday, September 17, 2019, on 68 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ENTA trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Multiple of Ten Bearish Other 0.00%
Inside Day Range Contraction 0.00%
Crossed Above 20 DMA Bullish -1.32%
Multiple of Ten Bearish Other -1.32%
Outside Day Range Expansion -1.32%
20 DMA Resistance Bearish 1.47%
Multiple of Ten Bearish Other 1.47%
20 DMA Resistance Bearish -0.62%
Multiple of Ten Bearish Other -0.62%

Older signals for ENTA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Chemistry Biotechnology Chemical Compounds Infection Infectious Disease Cyclopropanes Pyrrolidines Hepatitis C Hepatitis C Virus HCV Infection Ns3 Ns5a Viruses
Is ENTA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 106.8
52 Week Low 63.83
Average Volume 175,348
200-Day Moving Average 84.0853
50-Day Moving Average 74.3028
20-Day Moving Average 69.565
10-Day Moving Average 68.422
Average True Range 2.7061
ADX 28.64
+DI 15.0681
-DI 23.5905
Chandelier Exit (Long, 3 ATRs ) 66.2617
Chandelier Exit (Short, 3 ATRs ) 71.9483
Upper Bollinger Band 73.0314
Lower Bollinger Band 66.0986
Percent B (%b) 0.41
BandWidth 9.965931
MACD Line -1.5114
MACD Signal Line -1.9184
MACD Histogram 0.407
Fundamentals Value
Market Cap 1.32 Billion
Num Shares 19.1 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -63.86
Price-to-Sales 23.12
Price-to-Book 3.52
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 72.11
Resistance 3 (R3) 72.27 71.38 71.59
Resistance 2 (R2) 71.38 70.58 71.30 71.41
Resistance 1 (R1) 70.17 70.08 69.73 70.02 71.24
Pivot Point 69.28 69.28 69.06 69.20 69.28
Support 1 (S1) 68.08 68.48 67.63 67.92 66.70
Support 2 (S2) 67.19 67.99 67.11 66.53
Support 3 (S3) 65.98 67.19 66.35
Support 4 (S4) 65.83